BACKGROUND: The International Verapamil/Trandolapril Study (INVEST) demonstrated comparable efficacy between verapamil SR and atenolol antihypertensive treatment strategies for clinical outcomes and blood pressure (BP) control in hypertensive patients with coronary artery disease (N = 22,576). Effects of these antihypertension strategies on mood-related issues are not well understood. OBJECTIVES: The objectives of this study were 1) to compare depressive symptoms by strategy and 2) to identify predictors of depressive symptoms in INVEST patients after 1 year of follow up. DESIGN, SETTING, AND PATIENTS: Depressive symptoms were assessed in a subset (N = 2317) of consecutively randomized U.S. patients enrolled between April 1, 1999, and October 31, 1999. Patients were mailed surveys after randomization and after 1 year of treatment. INTERVENTION: Patients were assigned to either a verapamil SR or atenolol strategy to achieve Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure BP goals. Trandolapril and/or hydrochlorothiazide were recommended as add-on agents. MAIN OUTCOME MEASURE: Depressive symptoms were measured by the Center for Epidemiologic Studies-Depression (CES-D) scale. RESULTS:CES-D scores improved 1.45 points (p < .001) after 1 year in patients assigned to the verapamil SR strategy, whereas a nonsignificant improvement was observed in patients assigned to the atenolol strategy (0.27 points, p = .44). Predictors of higher depressive symptoms were higher baseline CES-D score (p < .001), history of depression diagnosis (p = .03), history of stroke (p < .001), and assignment to the atenolol strategy (p < .001). CONCLUSIONS: A verapamil SR strategy is a viable alternative to beta-blocker therapy for hypertensive patients with coronary artery disease, especially those at risk of depression.
RCT Entities:
BACKGROUND: The International Verapamil/Trandolapril Study (INVEST) demonstrated comparable efficacy between verapamil SR and atenolol antihypertensive treatment strategies for clinical outcomes and blood pressure (BP) control in hypertensivepatients with coronary artery disease (N = 22,576). Effects of these antihypertension strategies on mood-related issues are not well understood. OBJECTIVES: The objectives of this study were 1) to compare depressive symptoms by strategy and 2) to identify predictors of depressive symptoms in INVEST patients after 1 year of follow up. DESIGN, SETTING, AND PATIENTS: Depressive symptoms were assessed in a subset (N = 2317) of consecutively randomized U.S. patients enrolled between April 1, 1999, and October 31, 1999. Patients were mailed surveys after randomization and after 1 year of treatment. INTERVENTION: Patients were assigned to either a verapamil SR or atenolol strategy to achieve Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure BP goals. Trandolapril and/or hydrochlorothiazide were recommended as add-on agents. MAIN OUTCOME MEASURE: Depressive symptoms were measured by the Center for Epidemiologic Studies-Depression (CES-D) scale. RESULTS: CES-D scores improved 1.45 points (p < .001) after 1 year in patients assigned to the verapamil SR strategy, whereas a nonsignificant improvement was observed in patients assigned to the atenolol strategy (0.27 points, p = .44). Predictors of higher depressive symptoms were higher baseline CES-D score (p < .001), history of depression diagnosis (p = .03), history of stroke (p < .001), and assignment to the atenolol strategy (p < .001). CONCLUSIONS: A verapamil SR strategy is a viable alternative to beta-blocker therapy for hypertensivepatients with coronary artery disease, especially those at risk of depression.
Authors: Marie Krousel-Wood; Cara Joyce; Elizabeth Holt; Paul Muntner; Larry S Webber; Donald E Morisky; Edward D Frohlich; Richard N Re Journal: Hypertension Date: 2011-10-03 Impact factor: 10.190
Authors: Pranav K Gandhi; L Douglas Ried; Carole L Kimberlin; Teresa L Kauf; I-Chan Huang Journal: Expert Rev Pharmacoecon Outcomes Res Date: 2013-12 Impact factor: 2.217